CBT-I: The First-Line Treatment for Chronic Insomnia with Dr. Donn Posner (Part 1 of 2)
The Carlat Psychiatry PodcastShow Notes
Dr. Donn Posner is one of the most active educators in CBT-I. He's founder and president of Sleepwell Consultants, adjunct clinical associate professor in Psychiatry and Behavioral Sciences at Stanford, and spent twenty-five years before that as director of behavioral sleep medicine at the Sleep Disorders Center of Lifespan Hospitals. In this first of two episodes, Dr. Posner explains that chronic insomnia is a disorder in its own right — not just a symptom of something else — driven by perpetuating factors that become the targets of treatment. He covers: How insomnia disorder is defined, and what a proper CBT-I assessment looks like The sleep diary as the clinician's version of an X-ray The two core behavioral components — sleep restriction (more accurately, time-in-bed restriction) and stimulus control — and the mechanisms each one targets: homeostatic sleep drive and conditioned arousal Why sleep can't be willed — it's never under a patient's voluntary control How far the protocol can flex for individual patients The evidence base showing CBT-I works even alongside depression, anxiety, PTSD, or chronic pain — and that those conditions don't need to be treated first
Length: 28 Minutes
More from The Carlat Psychiatry Podcast
Dr. Andrew Christensen, distinguished research professor of psychology at UCLA and co-developer of Integrative Behavioral Couple Therapy (IBCT), explains how IBCT balances acceptance and change in treating relationship distress. He walks clinicians through the assessment and feedback process and the DEEP formulation, describes the three core interventions—empathic joining, unified detachment, and practical problem-solving—and discusses treatment length, termination, and training resources. Published On: October 19, 2026 Duration: 44 mins 19 seconds
Parents often come into treatment hoping an SSRI will make their child's OCD disappear. But how much relief do these medications actually provide? Today, we look at a large meta-analysis that gives us a more realistic picture of what SSRIs can and can't do for pediatric OCD.
Dr. Carla Sharp is a leading expert in Mentalization-Based Treatment (MBT), developmental psychopathology, and the treatment of personality disorders. She is the John and Rebecca Moores Professor of Clinical Psychology at the University of Houston, where she serves as Associate Dean for Faculty and Research and directs the Developmental Psychopathology Lab and the Adolescent Diagnosis, Assessment, Prevention, and Treatment Center. A prolific scholar with more than 380 peer-reviewed publications and eight books, she has made substantial contributions to the development and dissemination of mentalization-based approaches and is a certified supervisor and licensed trainer in MBT for both adults and adolescents. In this episode, Dr. Sharp offers a comprehensive introduction to MBT as a treatment for BPD — from what mentalizing is and how it develops through early “serve-and-return” interactions, to how disruptions in this capacity contribute to the difficulties characteristic of BPD. She takes clinicians inside an MBT session, explaining experience-near exploration, empathic validation, affect elaboration, and the mentalizing loop. She also unpacks the three pre-mentalizing modes — psychic equivalence, teleological mode, and pretend mode — and discusses the therapist’s use of self, the importance of maintaining a curious “not-knowing” stance, and how clinicians can recognize when a patient’s capacity to mentalize is strengthening.
Prescribing stimulants outside of ADHD is not illegal, but what Done did sent the clinical leader to jail. We look at what went wrong and what the charges were, and end with a research update that improves access to psychiatric care the honest way.
Done paid clinicians by the refill, not the visit. We trace how a telehealth company built its business model around stimulant prescriptions. Along the way you’ll learn why amphetamines are the #1 stimulant in America, but rarely used outside the US.Plus: a research update on tapering and switching sleep medication.